Most up-to-date research on "Global Hemophilia Market Report: 2015 Edition" to its huge collection of research reports.
Albany, NY -- (SBWIRE) -- 05/20/2015 -- Hemophilia is an inherited or acquired bleeding disorder that prevents blood from clotting. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. People with hemophilia do not bleed any faster than normal, but they can bleed for a longer time. Hemophilia is quite rare and about 1 in 10,000 people are born with it, around 0.42 million people live with hemophilia. Hemophilia patients need to replace the missing factor through infusions. The main treatment is called replacement therapy, in which concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are injected into a vein. More people suffer with hemophilia A in comparison to hemophilia B and Inhibitors. The US accounts for the major population suffering with hemophilia globally.
Browse Detail Report With TOC
The key trends observed in the market include introduction of new products increased competition in rFVIII market and adoption of prophylactic treatment. On the development front, there has been an increase in the launch of new products like next-Generation long-acting Factor VIII and ready-to-use product by Novo Nordisk. But there are certain challenges too which include high risk and cost associated with new drugs, rising cost of hemophilia treatment and low switching rate among patients. The future drivers of the industry are increased rate of diagnosis and treatment, rising male population and global healthcare expense among others.
Request for Sample Report
The report provides a comprehensive study of hemophilia market globally and also provides detailed information for key regional markets. The competition in the global hemophilia market is intense among large players like Baxter International Inc., Novo Nordisk and Pfizer. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.
By combining SPSS Inc.'s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Content
2. Market Analysis
2.1 Global Hemophilia Market
2.2 Hemophilia Market by Segments
2.2.1 Hemophilia A
Supply/Demand of Factor VIII
2.2.2 Hemophilia B
2.2.3 Hemophilia A & B with Inhibitors
2.2.4 Von Willebrand Disease
2.3 Regional Analysis
2.3.1 The US
For Market Research Latest Reports Visit
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Increased Rate of Diagnosis and Treatment
3.1.2 Rising Male Population
3.1.3 Rising Global Healthcare Expense
3.1.4 FDA Regulation and Patents
3.2 Key Trends
3.2.1 Introduction of New Products
3.2.2 Increased Competition in rFVIII Market
3.2.3 Adoption of Prophylactic Treatment
3.3.1 High Risk and Cost Associated with New Drugs
3.3.2 Rising Cost of Hemophilia Treatment
3.3.3 Low Switching Rate among Patients
3.4 Significant Developments
3.4.1 Next-Generation Long-Acting Factor VIII in Process
3.4.2 Ready-To -Use Product by Novo Nordisk
4. Competitive Landscape
Products in Development
4.2 The US
Verrucous Carcinoma Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, Verrucous Carcinoma Global Clinical Trials Review, H1, 2015" provides data on the Verrucous Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Verrucous Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the...
Uveal Melanoma Global Clinical Trials Review, H1, 2015
GlobalData's clinical trial report, Uveal Melanoma Global Clinical Trials Review, H1, 2015" provides data on the Uveal Melanoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Uveal Melanoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The...
Browse Our Press Releases on Prweb
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
Toll Free: 866-997-4948
90 State Street, Suite 700
Albany, NY 12207